A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients with Moderate to Severe Active Rheumatoid Arthritis
This randomised, double-blind, parallel workforce learn about will examine the efficacy and safety of subcutaneous (sc) versus intravenous (iv) administration of RoActemra/Actemra (tocilizumab) in patients with moderate to extreme active rheumatoid arthritis. Patients will likely be randomised to receive either RoActemra/Actemra 162 mg sc weekly plus iv placebo every four weeks, or RoActemra/Actemra eight mg/kg iv every 4 weeks plus sc placebo weekly throughout the double-blind duration from baseline to Week 24. The double-blind period will probably be followed via a 72-week open-label therapy with some switching of sc and iv admin
